IL1B and cryopyrin-associated periodic syndrome: All the three anti–IL-1 agents are currently recommended as first-line therapy in CAPS patients of any age, with a level of evidence 1B for canakinumab and rilonacept, and 2A for anakinra, and a strength of recommendation A and B, respectively (14).